IRD — Opus Genetics Share News
0.000.00%
Last trade - 00:00- $317.81m
- $265.20m
- $14.20m
Opus Genetics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Ocuphire Pharma announces acquisition of Opus Genetics
Brief: Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%
Brief: Ocuphire Pharma Says It Initiates Vega-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Presbyopia
Brief: Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Presbyopia
Ocuphire Pharma Inc reports results for the quarter ended in June - Earnings Summary
Ocuphire Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview
Ocuphire Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Ocuphire Pharma Says Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Brief: Ocuphire Pharma Announces Appointment Of George Magrath,
Ocuphire Pharma Inc expected to post a loss of 22 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
Ocuphire Pharma rises after FDA says it has approved company's eye drug
Brief: Ocuphire Pharma Inc - On August 10 Entered Into A Common Stock Purchase Agreement With Lincoln Park Capital Fund
Ocuphire Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ocuphire Pharma Q2 revenue USD 3.674 million
Ocuphire Pharma Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Ocuphire Presents APX3330 Zeta-1 Clinical Data In Late-Breaker Session
Brief: Ocuphire Presents APX3330 ZETA-1 Data At Clinical Trials At The Summit